Organigram Global Inc. key statistics and ratios

In fiscal 2025, Organigram Global Inc. had return on equity of -7.4%, an operating margin of -5.9%, debt equal to 0.0% of equity and a current ratio of 2.26. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Organigram Global Inc.: financial ratios, annual
Fiscal year	2018Aug 2018	2019Aug 2019	2020Aug 2020	2021Aug 2021	2022Aug 2022	2023Sept 2023	2024Sept 2024	2025Sept 2025
Gross margin	—	60.3%	−65.1%	−35.9%	21.7%	23.5%	29.7%	34.8%
Operating margin	293.0%	6.8%	−167.6%	−116.0%	−29.6%	−162.7%	−21.7%	−5.9%
Net margin	165.0%	−11.9%	−156.9%	−165.1%	−9.8%	−153.8%	−28.4%	−9.6%
Free-cash-flow margin	−556.3%	−178.9%	−141.0%	−51.0%	−58.3%	−42.0%	−0.5%	−9.5%
Return on equity	11.4%	−3.7%	−42.5%	−33.8%	−2.9%	−62.7%	−15.6%	−7.4%
Return on assets	6.9%	−2.6%	−30.8%	−26.7%	−2.6%	−55.8%	−12.8%	−5.0%
Asset turnover	0.04	0.22	0.20	0.16	0.26	0.36	0.45	0.53
Current ratio	18.06	4.47	5.85	9.92	4.01	6.95	4.92	2.26
Debt to equity	1.8%	15.2%	38.5%	0.1%	0.0%	0.1%	0.0%	0.0%
Interest cover (operating income ÷ interest)	—	—	n/m	n/m	n/m	n/m	n/m	n/m
Effective tax rate	20.4%	—	—	—	—	—	—	—
R&D as % of revenue	0.0%	0.5%	1.5%	4.6%	4.1%	8.2%	7.0%	4.2%
Capital spending as % of revenue	454.1%	135.3%	89.0%	14.9%	33.4%	18.0%	3.0%	6.6%
Free cash flow ÷ net income	−337.0%	—	—	—	—	—	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

5 of 7 checks passed · September 30, 2025

What it owns · $404m

Short-term assets $205mLonger-term assets $199m

What it owes, and who funded it · $404m

Short-term liabilities $91mLonger-term liabilities $62mShareholders' equity $251m

Short-term assets cover short-term liabilities $205m of assets due within a year against $91m of liabilities due within a year.
Short-term assets cover long-term liabilities $205m short-term assets against $62m of longer-dated liabilities.
More cash than debt $60m of cash against $17,951 of debt.
Debt below 40% of shareholders' equity Debt is 0% of equity.
Debt burden no higher than five years ago Debt to equity moved from 35% to 0% over five years.
A year's operating cash flow covers at least 20% of debt −$5m of operating cash flow against $17,951 of debt.
Operating profit covers interest at least five times over Operating income of −$11m against $396,287 of interest.

From Organigram Global Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BTMD vs OGI KMDA vs OGI CRON vs OGI

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Organigram Global Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Organigram Global Inc.